COLUMBUS, Ohio / Nov 01, 2024 / Business Wire / Mettler-Toledo International Inc. (NYSE: MTD) today announced it will present at the UBS Global Healthcare Conference on Wednesday, November 13 at 11 a.m. EST, and the Stifel Healthcare Conference on Tuesday, November 19 at 1:15 p.m. EST.
The Company will also present at the 7th Annual Evercore ISI HealthCONx Conference on Wednesday, December 4 at 9:10 a.m. EST. A live webcast of the presentations will be available on the Company’s investor relations website at investor.mt.com.
METTLER TOLEDO (NYSE: MTD) is a leading global supplier of precision instruments and services. We have strong leadership positions in all of our businesses and believe we hold global number-one market positions in most of them. We are recognized as an innovation leader and our solutions are critical in key R&D, quality control, and manufacturing processes for customers in a wide range of industries including life sciences, food, and chemicals. Our sales and service network is one of the most extensive in the industry. Our products are sold in more than 140 countries and we have a direct presence in approximately 40 countries. With proven growth strategies and a focus on execution, we have achieved a long-term track record of strong financial performance. For more information, please visit www.mt.com.
Last Trade: | US$1,004.96 |
Daily Change: | -11.69 -1.15 |
Daily Volume: | 209,770 |
Market Cap: | US$21.200B |
November 07, 2024 August 01, 2024 May 25, 2023 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load